S J Seung1, A N Traore1,2,3,4, B Pourmirza2, K E Fathers2, M Coombes3, K J Jerzak4. 1. hope Research Centre, Sunnybrook Research Institute, Toronto, ON. 2. Department of Medical Affairs, Hoffmann-La Roche Limited, Mississauga, ON. 3. Market Access and Pricing Department, Hoffmann-La Roche Limited, Mississauga, ON. 4. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON.
Abstract
Background: Breast cancer (bca) is the type of cancer most frequently diagnosed among women in Canada. Breast cancer is categorized into various molecular subtypes by the expression of estrogen receptor (er), progesterone receptor (pgr), and her2 (human epidermal growth factor receptor 2). Currently, Canada has no national cancer registry with epidemiology data by subtype. Thus, we conducted a study to determine incidence, survival, and clinicopathologic characteristics by bca subtype [triple negative breast cancer (tnbc); her2+; and hormone receptor-positive (hr+), her2-] in Canadian women newly diagnosed with bca. Methods: Female patients diagnosed between 1 April 2012 and 31 March 2016 (fiscal 2012-2015) were identified in the Ontario Cancer Registry, and individual patient data were linked to data in provincial health administrative databases. Descriptive statistics and Kaplan-Meier curves were generated. Results: In this cohort, 3277 women (9.5%) had tnbc, 4902 (14.3%) had her2+ bca, and 22,247 (64.8%) had hr+, her2-breast cancer. The annual incidence was 15 per 100,000 for the tnbc group, 21-23 per 100,000 for the her2+ group, and 97-105 per 100,000 for the hr+, her2- group. The lowest median overall survival (mos) of 8.9 months was observed in women with clinical stage iv tnbc. In comparison, the mos was 37.3 months in those with her2+ disease and 35.2 months in those with and hr+, her2- metastatic bca. Conclusions: In the present study, the most recent and largest administrative database analysis of a Canadian population to date, we observed a subtype distribution consistent with previously reported data, together with comparable annual incidence and overall survival patterns. 2020 Multimed Inc.
Background: Breast cancer (bca) is the type of cancer most frequently diagnosed among women in Canada. Breast cancer is categorized into various molecular subtypes by the expression of estrogen receptor (er), progesterone receptor (pgr), and her2 (humanepidermal growth factor receptor 2). Currently, Canada has no national cancer registry with epidemiology data by subtype. Thus, we conducted a study to determine incidence, survival, and clinicopathologic characteristics by bca subtype [triple negative breast cancer (tnbc); her2+; and hormone receptor-positive (hr+), her2-] in Canadian women newly diagnosed with bca. Methods: Female patients diagnosed between 1 April 2012 and 31 March 2016 (fiscal 2012-2015) were identified in the Ontario Cancer Registry, and individual patient data were linked to data in provincial health administrative databases. Descriptive statistics and Kaplan-Meier curves were generated. Results: In this cohort, 3277 women (9.5%) had tnbc, 4902 (14.3%) had her2+ bca, and 22,247 (64.8%) had hr+, her2-breast cancer. The annual incidence was 15 per 100,000 for the tnbc group, 21-23 per 100,000 for the her2+ group, and 97-105 per 100,000 for the hr+, her2- group. The lowest median overall survival (mos) of 8.9 months was observed in women with clinical stage iv tnbc. In comparison, the mos was 37.3 months in those with her2+ disease and 35.2 months in those with and hr+, her2- metastatic bca. Conclusions: In the present study, the most recent and largest administrative database analysis of a Canadian population to date, we observed a subtype distribution consistent with previously reported data, together with comparable annual incidence and overall survival patterns. 2020 Multimed Inc.
Entities:
Keywords:
Breast cancer, subtypes; epidemiology; incidence; overall survival
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Victor R Grann; Andrea B Troxel; Naseem J Zojwalla; Judith S Jacobson; Dawn Hershman; Alfred I Neugut Journal: Cancer Date: 2005-06-01 Impact factor: 6.860
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Y H Park; S J Lee; E Y Cho; Y La Choi; J E Lee; S J Nam; J-H Yang; J H Shin; E Y Ko; B-K Han; J S Ahn; Y-H Im Journal: Ann Oncol Date: 2011-01-17 Impact factor: 32.976
Authors: Farrah Kassam; Katherine Enright; Rebecca Dent; George Dranitsaris; Jeff Myers; Candi Flynn; Michael Fralick; Ritu Kumar; Mark Clemons Journal: Clin Breast Cancer Date: 2009-02 Impact factor: 3.225
Authors: Yizhuo Kelly Gao; Markus Kuksis; Badr Id Said; Rania Chehade; Alex Kiss; William Tran; Faisal Sickandar; Arjun Sahgal; Ellen Warner; Hany Soliman; Katarzyna J Jerzak Journal: Oncologist Date: 2021-09-21
Authors: Christine Brezden-Masley; Kelly E Fathers; Megan E Coombes; Behin Pourmirza; Cloris Xue; Katarzyna J Jerzak Journal: Breast Cancer Res Treat Date: 2020-10-16 Impact factor: 4.872
Authors: Teresa C O Tsui; Maureen Trudeau; Nicholas Mitsakakis; Sofia Torres; Karen E Bremner; Doyoung Kim; Aileen M Davis; Murray D Krahn Journal: PLoS One Date: 2022-02-04 Impact factor: 3.240
Authors: Kimberly A Burton; Elisabeth Mahen; Eric Quentin Konnick; Sibel Blau; Michael O Dorschner; Arturo B Ramirez; Stephen C Schmechel; Chaozhong Song; Rahul Parulkar; Stephanie Parker; Francis Mark Senecal; Colin C Pritchard; Brigham H Mecham; Christopher Szeto; Patricia Spilman; Jingchun Zhu; Vijayakrishna K Gadi; Roy Ronen; Jackie Stilwell; Eric Kaldjian; Janusz Dutkowski; Stephen Charles Benz; Shahrooz Rabizadeh; Patrick Soon-Shiong; C Anthony Blau Journal: JCO Precis Oncol Date: 2022-03
Authors: Christine Brezden-Masley; Kelly E Fathers; Megan E Coombes; Behin Pourmirza; Cloris Xue; Katarzyna J Jerzak Journal: Breast Cancer Res Treat Date: 2020-10-22 Impact factor: 4.872